tolerated the drug as well as other subjects in the studies tolerated cephalexin, and while some pharmacokinetic parameters of MDL 19,592 and cephalexin were different, both serum clearance and percent recovery of drug in the urine were essentially the same for the two cephalosporins.4) Two of the 8 subjects who had received 4 g of MDL 19,592 per day developed rashes after the tenth day of treatment.
Materials and Methods
Antibiotics MDL 19,592 was prepared in our laboratories and is a white crystalline powder that is slightly soluble in water. Cephalexin, cefaclor, cephalothin, and cefazolin were obtained from Eli Lilly and Co.; methicillin, oxacillin, cloxacillin, and dicloxacillin from Bristol Laboratories; cephradine from E. R. Squibb & Sons, Inc.; cefroxadine (CGP 9000) from Ciba-Geigy Corp.; cefadroxil from Mead Johnson Laboratories; and nafcillin from Wyeth Laboratories.
Antibiotic Spectrum All bacterial strains were clinical isolates. Minimal inhibitory concentrations (MICs) were determined by diluting antibiotics in a suitable agar medium and inoculating the agar surface with 0.003 ml of diluted culture using the multiple inoculator of STEERS et al.° . Serial twofold dilutions of antibiotic were used for all MIC determinations except where streptococci were concerned. For those organisms, the incremental difference in concentrations employed in a series was 0.1 tag/ml. For routine MIC determinations, all cultures except Streptococcus pneumoniae, Streptococcus pyogenes, Neisseria gonorrhoeae, H. influenzae and anaerobes were grown for 18 hours in Trypticase soy broth (TSB; Difco) and diluted in Mueller-Hinton broth (MHB; BBL) to obtain approximately 2 x 105 colony-forming units (cfu) of staphylococci and 4 x 104 cfu of the other organisms as inocula. S. pneumoniae and S. pyogenes were grown for 24 hours in brain heart infusion broth (BHIB; Difco) and diluted in BHIB to obtain about 2 x 106 cfu as inocula. H. influenzae cultures were grown 24 hours in BHIB containing 1 % Supplement C (Difco) and diluted 1/100 in the same broth. Strains of N. gonorrhoeae were grown for 24 hours as spread plates on GC agar base (BBL) supplemented with 1 % hemoglobin (BBL) and 1 % Isovitalex (BBL). Surface growth from one plate suspended in 100 ml TSB served as inoculum. Anaerobes were grown for 48 hours in thioglycolate broth (BBL) and diluted 1/10 in MHB. MICs for H. influenzae and N. gonorrhoeae were determined using the supplemented GC agar described above. MICs for anaerobes were obtained using Mueller-Hinton agar (MHA; BBL) containing 1 % Supplement C. MICs for all other cultures were determined using MHA. Plates containing H. influenzae and N. gonorrhoeae were incubated for 24 hours in an atmosphere of 6 % carbon dioxide in air; those containing anaerobes were incubated for 48 hours in a Gas Pak 100 Anaerobic System (BBL); all other plates were incubated for 18 hours in air. All cultures were grown at 37°C, and after incubation, the lowest concentration of antibiotic allowing no or essentially no growth was considered to be the MIC.
Antibiotic Kill Rate Staphylococcus aureus killing curves were obtained by inoculating antibiotic-containing MHB with 18-hour cultures. Samples taken were diluted and added to MHA to make pour plates. After 18 to 24 hours incubation at 37°C, the cfu were counted.
Susceptibility to S. aureus Penicillinases
Cultures were grown and induced their i3-lactamases with methicillin according to the method of RICHMOND6). Cells were removed by centrifugation and ammonium sulfate added to the centrifugate until 60% saturation was achieved. The precipitate was collected by centrifugation, dissolved in a minimal amount of 0.1 M sodium acetate buffer, pH 5.9, and dialyzed against the same buffer overnight at 4°C. The dialysate was frozen and stored at -20°C until used. The concentrated enzyme preparation was diluted in 0.1 M sodium -potassium phosphate buffer, pH 7.0, so that when benzylpenicillin was added to saturate the enzyme, 2 to 3 ymol were hydrolyzed at a linear rate over 15 minutes at 37°C. The cephalosporins tested were added to the same enzyme preparations and the reaction mixtures incubated 3 hours. Samples were taken at prescribed intervals, fast frozen in acetone chilled with dry ice and stored at -20°C until assayed. Samples to be assayed were thawed and kept in an ice bath until assayed by an agar diffusion method using antibiotic medium 2 (Difco) seeded with Micrococcus luteus ATCC 9341. Standard curves were prepared from zone of inhibition responses obtained with known concentrations of phosphate-buffered antibiotics applied to 6 mm discs. Responses obtained with samples diluted in buffer were referred to standard curves to determine antibiotic concentrations.
Treatment of Experimental Infections in Mice
Charles River albino CD-1 male mice weighing 20 I g were infected by intraperitoneal injection of a bacterial suspension containing a sufficient number of organisms to produce uniformly lethal infections within 72 hours. The suspensions, prepared in BHIB from overnight cultures, were 0.1 to 1.0 ml in volume, depending upon the organism. Those of Escherichia coli and S. aureus strains M202, M238, and M258 contained 2.5 % hog gastric mucin. Groups of ten mice each were treated orally or subcutaneously with appropriate concentrations of antibiotic (representing a series of two or four-fold dilutions) at I and 4 hours after infection. The number of mice in each group surviving the challenge for 4 days was recorded and the ED50 (the dose in mg/kg required to protect 50 % of the infected mice) determined by BERKSON'S minimum chi square method7).
Antibiotic Levels in Mouse Serum MDL 19,592 and cephalexin were administered in water per os to albino CD-I male mice weighing 25 + 1 g. Four mice were bled from their orbital sinuses for each sampling time and sacrificed. The blood was pooled and the serum samples collected were bioassayed by the agar diffusion method using M. luteus. Samples were diluted in serum and assayed against standard curves plotted from results obtained with known concentrations of antibiotics added to serum.
Urinary Excretion of MDL 19,592
Urine samples were collected from five albino CD-1 male mice weighing 20 y1 g 60 minutes after per os dosing with MDL 19,592 at 80 mg/kg; each mouse was dosed with antibiotic in 0.25 ml of water. Pooled urine samples from dosed and non-dosed mice were chromatographed on cellulose Chromogram sheets (Eastman 13254) previously impregnated with 0.1 M potassium citrate buffer, pH 4.5, and dried. The chromatograms were developed ascendingly with acetone -H2O (3: 1), examined under ultraviolet light, and then bioautographed on antibiotic medium #1 (Difco) seeded with Bacillus subtilis ATCC 6633.
Mouse Serum Binding Twenty albino CD-1 male mice, each weighing 24 + 1 g were dosed with MDL 19,592 or cephalexin at 40 mg/kg and bled from the orbital sinuses at 30 to 40 minutes after dosing. The blood samples from each group were pooled and the serum collected. Additionally, the cephalosporins were added to mouse serum at a concentration of 25 ug/ml and the samples incubated for 30 minutes at 37°C. An aliquot of each sample was transferred to an Amicon Centriflo ultrafiltration membrane cone (2100 CF50) and the protein-free filtrate obtained by centrifugation for 20 minutes at 500 x g at 4°C. The antibiotic concentrations in protein-free filtrates and sera were determined by bioassay using M. luteus. Serum samples were assayed as described above. Protein-free filtrates were diluted in 0.1 M potassium phosphate buffer, pH 7.4, and assayed against standard curves established from results obtained with antibiotics dissolved in phosphate buffer (protein-free filtrate had no effect on the response of M. luteus to these antibiotics).
Results and Discussion
Studies In Vitro When compared to cephalexin against a selected group of organisms, MDL 19,592 was more potent for Gram-positive and cephalexin more potent for Gram-negative bacteria (Table 1) . Limited testing against other members of the Enterobacteriaceae not shown found cephalexin to be the more potent of the two compounds wherever activity was observed; neither showed noteworthy activity against Serratia OCT. 1983 marcescens, Proteus vulgaris or Proteus inconstans. Against H. influenzae, MDL 19,592 was essentially as effective as cephalexin. Both compounds had MICs of 12.5 jig/ml for 8 out of 11 ampicillinsensitive and 10 out of 12 ampicillin-resistant strains. The other 5 strains were inhibited at 25 lig/ml or higher, depending upon the strain and the compound. With respect to other organisms, neither compound was effective or significantly so against strains of enterococci, Pseudomonas aeruginosa, N. gonorrhoeae or Bacteroides fragilis. aureus were used in a study to determine the effect of inoculum size on the MICs of MDL 19,592 and other orally absorbed cephalosporins (Table 2) . MDL 19,592 was two to three times more potent than cephalexin, cephradine, and cefadroxil at all three inoculum levels tested. As compared to cefroxadine and cefaclor, MDL 19,592 also was two to three times more potent at the lowest inoculum level, but at the two higher levels, it was more potent than the other two compounds by a factor equal to or greater than seven. The in vivo results described later illustrate the fact that MICs obtained using an inoculum of 2 x 104 cfu, a level that is recommended for agar dilution tests", are not predictive of in vivo efficacy in our studies. Results of additional studies using a larger number of resistant strains of S. aureus, including the seven shown in Table 2 , confirmed the superiority of MDL 19,592 over the other orals tested (Table 3) . Although not shown, this superiority was observed for each strain tested. The results obtained with cefaclor and cefroxadine suggest that they are relatively labile to S. aureus penicillinase. As shown in Table 4 , MDL 19,592 was the most potent of the six compounds tested against representative benzylpenicillin-resistant strains of Staphylococcus epidermidis and sensitive strains of S.
aureus. Against S. pyogenes and S. pneumoniae, MDL 19,592 was slightly more potent than cephalexin (Table 5) .
Because MDL 19,592 was more potent in vitro than the other oral cephalosporins against staphylococci, it was of interest to compare it to cephalexin and cephradine (the next most potent compounds) to assess their respective abilities to kill cells of four penicillin-resistant strains of S. aureus. As shown in Fig. 2a , MDL 19,592 and cephalexin were more bactericidal than cephradine over the first 3 hours at 50 ,ug/ml and 6 hours at 20 yg/ml for strain M238. The rate of kill between 6 and 24 hours was greater at the lower concentration for all three compounds. When tested against strain M235, all compounds showed similar killing rates at 50µg/ml; however, at 20µg/ml only MDL 19,592 reduced the population at a much faster rate than it did at 50 µg/ml (Fig. 2b) . The more rapid kill rates observed for strains M238 and M235 at the lower concentrations of cephalosporin may be a reflection of the Eagle effect',") in which a relatively low as opposed to a high concentration of a ~-lactam compound kills at the faster rate. Against strain M261 at 50 Etg/ml, MDL 19,592 and cephalexin killed at essentially an identical rate over 24 hours, a rate that was faster than that observed with cephradine (Fig. 2c ). Of the strains tested, all three compounds at 50 jig/ml killed cells of strain M249 at the fastest rate, with all compounds killing at the same rate. An initial population of 3 x 109 cfu/ml was reduced to about 101 cfu/ml at 6 hours and about 103 cfu/ml at 24 hours. Thus, MDL 19,592 was as effective or more effective than cephalexin and cephradine in killing strains of resistant S. aureus.
While cephradine was occasionally less effective than the other two compounds, it is not known whether this is significant.
As expected, MDL 19,592 was found to be quite resistant to S. aureus penicillinases. When the rate of hydrolysis of benzylpenicillin by penicillinases from four strains was assigned the value of 2,000, 
Studies In Vivo
As compared to cephalexin and cephradine, MDL 19,592 was the superior drug against S. aureus infections caused by benzylpenicillin-resistant and sensitive strains, being generally two to three times more effective than the other compounds (Table 6 ). In a second series of studies that only included the resistant strains, MDL 19,592 also was found to be superior to the newer orals, as well (Table 6) . While cefadroxil was similar to cephalexin and cephradine in comparisons with MDL 19,592, cefaclor was clearly the least active of the drugs tested with cefroxadine being the next least active. Under our conditions, the in vivo results best reflect the results obtained in vitro using dense inocula (Tables 2 and 3) , as mentioned previously.
Amongst the parenteral cephalosporins, cephalothin and cefazolin are commonly used against S.
aureus infections in man. When administered orally or subcutaneously, MDL 19,592 was significantly superior to either compound against these infections in mice caused by resistant strains. It was more effective than cephalothin against one of the two infections caused by sensitive strains and equally effective as cefazolin against both of the sensitive strains ( Table 7) . The poor potency of cephalothin for strain M202 cannot be explained; similar results were obtained in other tests. As can be seen, the MIC data for these compounds were not predictive of in vivo efficacy. In these studies, this probably partially reflects differences in serum-binding, MDL 19,592 being minimally so (shown later); and in the case of cephalothin, its metabolism by the mouse is extensive", 12). Certain penicillins are often described as being the "drugs of first choice" for infections caused by benzylpenicillin-resistant S. aureus. When compared with these compounds in vivo, MDL 19,592 administered orally or subcutaneously was superior to nafcillin, dicloxacillin, oxacillin, and methicillin administered subcutaneously and/or orally ( Table 8 ). The in vitro potency of nafcillin and the isoxazole penicillins was not predictive of in vivo efficacy in these studies either. This could, at least in part, reflect the high serum-binding of these j3-lactam antibiotics.
With respect to other model infections, MDL 19,592 was superior to cephalexin in vivo against S. pyogenes and marginally superior against one of two S. pneumoniae model infections (Table 9) . And, See Table 7 . b See footnote c Table 7 . Compounds were dissolved or suspended in 5 % NaHCO3 and administered 1 and 4 hours after infection. b Average of two tests . as expected, cephalexin was superior to MDL 19,592 against Gram-negative bacterial infections (Table   10 ). Only limited testing against Gram-negative bacteria in vivo was warranted based upon results obtained in vitro.
Concentrations of MDL 19,592 and cephalexin attained in blood serum of mice after oral administration at 40 mg/kg are shown in Fig. 3 . Both drugs were rapidly absorbed, with the highest blood levels being observed at 15 minutes; these were 53 and 43 ug/ml for MDL 19,592 and cephalexin, respectively. As shown, the blood levels of the two antibiotics declined at a similar rate. A fairly linear dose response was obtained when MDL 19,592 was given orally at levels from 5 to 80 mg/kg. For example, at 80 mg/kg, the peak blood level (at 10 to 15 minutes) was about 85 ug/ml. As determined by an ultrafiltration method, serum from mice dosed with MDL 19,592 or cephalexin bound the antibiotics only 11 and 4%, respectively. Similar results were obtained with spiked serum. Urine collected from mice at 60 minutes after an 80 mg/kg oral dose of MDL 19,592 contained the antibiotic as the only bioactive entity as determined by chromatography coupled with bioautography.
In summary, the very favorable results obtained with MDL 19,592 as compared to other j3-lactam compounds against benzylpenicillin-resistant S. aureus in vivo as well as the good results obtained against streptococcal mouse infections indicated that MDL 19,592 had clinical potential for treating otitis media and infections of the respiratory tract, skin, skin structures, bone and urinary tract caused by susceptible organisms. It also was felt that its lower potency and narrower spectrum of activity for genera of the Enterobacteriaceae as compared to other oral cephalosporins could be viewed as a plus if one considered that its primary potential use would be against Gram-positive coccal infections. Thus, as mentioned in the introduction, single and multiple-dose pharmacokinetic and safety studies in humans were conducted3,4).
